TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06121544

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma tau
Description: Plasma levels of different p-tau and np-tau species

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma tau
Description: Plasma levels of different p-tau and np-tau species

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: Plasma levels of Ab42/Ab40 ratio

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: Plasma levels of Ab42/Ab40 ratio

Intervention type: DIAGNOSTIC_TEST
Intervention: Flutemetamol F18 Injection
Description: Positron emission tomography (PET) imaging of amyloid-β plaques

Intervention type: DIAGNOSTIC_TEST
Intervention: Flutemetamol F18 Injection
Description: Positron emission tomography (PET) imaging of amyloid-β plaques

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-RO6958948 Injection
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-RO6958948 Injection
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Different MRI sequences relevant for brain imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Different MRI sequences relevant for brain imaging
Study: NCT06630442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend a food safety educational training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06118255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenfluramine
Description: The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).
Study: NCT06357143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REMOVE
Description: INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
Study: NCT06570551

Intervention type: DEVICE
Intervention: i3 CGM(continuous glucose monitor)
Description: The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.

Intervention type: DEVICE
Intervention: i3 CGM(continuous glucose monitor)
Description: The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.
Study: NCT05615220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam Hydrochloride
Description: Selective dopamine D1 and D5 receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecopipam Hydrochloride
Description: Selective dopamine D1 and D5 receptor antagonist
Study: NCT05507437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIN816 70 mg lyophilisate powder
Description: Recombinant human CD39 enzyme

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile sodium chloride solution
Study: NCT06077513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAD-CAM designed and preprinted Ti-Mesh frame
Description: CAD-CAM technology which is the process of designing and manufacturing a custom-made dental device, or a patient-specific dental device from an industrialized product, with the aid of a computer.will be used to plan and preprint a 3-D Ti-Mesh frame prior to the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chairside fabrication of Ti-Mesh frame
Description: A three-dimensional frame or cage of Ti-Mesh or Ti-reinforced d-polytetrafluoroethylene (PTFE) will be fashioned during the surgery to contain, shape and stabilize the bone graft materials (the internal scaffold). This 3-D frame will be custom fabricated from a perforated Ti Mesh sheet material at the time of surgery which takes considerable time and skill.
Study: NCT05787249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nudge
Description: Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
Study: NCT05838573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin treatment
Description: Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
Study: NCT05787249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nudge
Description: Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider nudge
Description: Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider nudge
Description: Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
Study: NCT05910424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of saliva, gum fluid and/or dental plaque samples
Description: Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs
Study: NCT05838573

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline assessments
Description: Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volunteer assessments
Description: Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
Study: NCT05626660

Intervention type: OTHER
Intervention: Coronary angiography and percutaneous coronary intervention
Description: Coronary angiography and percutaneous coronary intervention via radial approach

Intervention type: OTHER
Intervention: Coronary angiography and percutaneous coronary intervention
Description: Coronary angiography and percutaneous coronary intervention via radial approach
Study: NCT06583590

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum toxin A
Description: Botulinum toxin (BoNT) is One of the most potent toxins known to humans produced by Clostridium botulinum that has been used to treat several striated and smooth muscle disorders. Because the pathophysiology and the reason for patients' lack of response to PDE5I is insufficient smooth muscle relaxation and veno-occlusive disorder (VOD) , BTX-A may prove to be a viable treatment for this patient population due to its availability to facilitate long-acting cavernosal smooth muscle relaxation by inhibition of the release of noradrenaline from the adrenergic neurons acting on the cavernosal smooth muscle. Thus, the dominant sympathetic basal tone of the cavernosal smooth muscle is essentially removed, facilitating the occurrence of an erection.

Intervention type: DRUG
Group type: OTHER
Intervention: Tadalafil 5mg
Description: Tadalafil is one of 5-phosphodiesterase inhibitors that used to treat male sexual function problems (impotence or erectile dysfunction-ED). In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tadalafil is thought to work by relaxing the smooth muscle in the prostate and bladder.
Study: NCT05601583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
Study: NCT05588141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib
Description: Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib
Description: Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib
Description: Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
Study: NCT06352294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability training
Description: Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training and myofascial relase
Description: Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult. In addition, myofascial relaxation will be applied with roller bar along the superficial back line.
Study: NCT06056674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U-PEACE Intervention
Description: This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAU
Description: Participants in this group will continue to receive standard of care within their school clinic.
Study: NCT05887323

Intervention type: DEVICE
Intervention: Implantation of the Tendril 2088 lead in the LBBA
Description: Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
Study: NCT05919849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief online writing intervention
Description: Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief online writing intervention
Description: Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.

Intervention type: OTHER
Group type: OTHER
Intervention: Control condition
Description: Participants will be instructed to write in order to control for time and writing engagement.
Study: NCT05724173

Intervention type: DEVICE
Group type: OTHER
Intervention: BrainGate Neural Interface System
Description: Placement of the BrainGate2 sensor(s) into the speech-related cortex
Study: NCT06544928

Intervention type: DEVICE
Intervention: RESP Biosensor
Description: The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
Study: NCT05824351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tanzanian beeswax-pine resin
Description: Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Domestic beeswax-pine resin
Description: Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hollister's AdaptTM Barrier Rings
Description: Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
Study: NCT05953350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
Description: hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
Description: After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
Study: NCT05607563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009 injection
Description: Participants receive PM1009 intravenously, every 2 weeks
Study: NCT06470776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot counselling
Description: Access to a chatbot that provides smoking cessation counselling based on the 5A's (Ask, Advice, Assess, Assist, Arrange follow-up) and 5R's (Risk, Relevance, Rewards, Relevance, Roadblocks, Repetition) tobacco intervention models from baseline to 3-month post-baseline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer counselling
Description: Usual treatment provided by the Youth Quitline, i.e., telephone counselling for smoking cessation based on the 5As and 5Rs models delivered by trained peer counsellors at baseline and 1 week, 1 month and 3 months post-baseline
Study: NCT06047808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Through Music
Description: Storytelling Through Music is a six-week expressive arts intervention.
Study: NCT04961294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture
Description: Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
Study: NCT04380844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beprevent
Description: 10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
Study: NCT05611580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Risk Reduction
Description: The intervention involves education information about chronic diseases and way to reduce risk for developing chronic diseases and/or decrease worsening of existing conditions.
Study: NCT04742855

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
Study: NCT06565182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention consists of two different types of moderate intensity exercise: Continuous aerobic and resistance exercise.
Study: NCT04827459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Coach App
Description: Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
Study: NCT06575959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral tablet
Study: NCT05714033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilatory Strategy To Prevent Atelectasis
Description: Given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Decubitus Strategy (LADS)
Description: Given
Study: NCT04863885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive Nivoumab 1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive Nivoumab 1mg/kg
Study: NCT05363410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MagnéVie B6®
Description: micronutrient supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo supplement
Study: NCT06196034

Intervention type: GENETIC
Intervention: No intervention
Description: No intervention

Intervention type: GENETIC
Intervention: No intervention
Description: No intervention
Study: NCT06407232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: 480 mg taken orally once daily, for 84 days
Study: NCT06309186

Intervention type: OTHER
Intervention: Evaluation of midwifes' burnout
Description: Burnout evaluated by questionnaires
Study: NCT06452589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FieldForce Ablation System
Description: The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.
Study: NCT05770245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study: NCT06498258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy Balance Model Based Psychoeducation
Description: In this study, it can be said that adopting a loving, connected and balanced state of mind in the face of the difficulties experienced and responsibilities undertaken by caregivers will increase the joy, meaning and self-sufficiency in life and as a result, it can positively contribute to their level of well-being. All these results are important for caregivers to be able to recognise their own resources, to maintain their life balance, to develop a positive perspective towards themselves, to make subjective evaluations and to recognise their strengths.
Study: NCT05284084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed Head elevation, H2 blockers and mouth wash
Description: Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Data collection for comparison
Description: Data collection for comparison

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection for comparison
Description: Data collection for comparison
Study: NCT05853809

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FeNO measurement
Description: FeNO measurement to guide anti-inflammatory asthma treatment
Study: NCT04846842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Description: Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.